Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from October 28, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 26, 2026 — +21.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$52.00 – $53.30Entry zone — fair-value band

$52.58Published — price the day we called it

$61.52Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$63.98Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 80 days.

At window close

+21.7%

realized, from the publication price to the last close inside the window

Peak gain

+22%

peak, from the publication price — not a realized return

S&P 500, same window

+1.1%

SPY over the identical days, dividend-adjusted

Window close

$63.98

last close inside the window, ended January 26, 2026

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Days to target

The thesis — published October 28, 2025

Predicted growth

+17%

over the measurement window

Target price

$61.52

the price the thesis aimed for

Entry zone

$52.00 – $53.30

the fair-value band we waited for

Price at publication

$52.58

published October 28, 2025

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

NVO looks like a strong company whose stock has fallen more than usual, while investor mood stays positive. Upcoming Wegovy liver-disease study results at a major medical meeting could refresh interest after a small analyst target cut. Because Novo Nordisk leads in obesity medicines and the market backdrop is decent, a bounce seems reasonable. Main watch-outs: rivals, tight supply, and pressure on prices.

Primary drivers

Stock looks unusually beaten down, creating a potential near-term recovery setup.
Near-term Wegovy liver study results may spark fresh interest and media attention.
Company is the clear leader in modern obesity drugs, a fast-growing treatment area.
Investor mood remains upbeat despite a small analyst target cut recently.

How it played out

NVO: target reached in 80 days

Lyra published NVO at 52.58 on 2025-10-28 with an expected gain of 17%. The thesis pointed to an unusually beaten-down stock, possible interest from upcoming Wegovy liver study results, Novo Nordisk's lead in modern obesity drugs, and investor mood that stayed upbeat despite a small analyst target cut. It also named rivals, tight supply, and pricing pressure as watch-outs.

Inside the window, the stock reached the 61.52 target in 80 days. It peaked at 64.16 on 2026-01-23, a 22% gain. It ended at 63.98 on 2026-01-26. The published thesis played out.

What happened during the window

On 2025-11-05, Novo Nordisk reported third-quarter results and reduced its full-year outlook. On 2026-01-05, the company launched an oral Wegovy weight-loss pill in the U.S.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals